A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT00457392
First received: April 4, 2007
Last updated: September 24, 2013
Last verified: September 2013

April 4, 2007
September 24, 2013
July 2007
July 2010   (final data collection date for primary outcome measure)
Overall Survival (OS) [ Time Frame: Baseline to death or 28 days after last dose for the last participant ] [ Designated as safety issue: No ]
Overall survival is the duration from assignment to study medication to death. For participants who are alive, overall survival is censored at the last contact.
Overall survival for erlotinib plus SU011248 versus erlotinib plus placebo as treatment for platinum-refractory non-small cell lung cancer.
Complete list of historical versions of study NCT00457392 on ClinicalTrials.gov Archive Site
  • Progression-Free Survival (PFS) [ Time Frame: Baseline to disease progression or death due to any cause or 28 days after last dose ] [ Designated as safety issue: No ]
    Time in weeks from assignment to study medication to first documentation of objective tumor progression or death due to any cause. PFS was calculated as (first event date minus the date of first dose of study medication plus 1) divided by 7. Tumor progression was determined from oncologic assessment data (where data meet the criteria for progressive disease [PD]), or from adverse event (AE) data (where the outcome was "Death").
  • Percentage of Participants With Objective Response (OR) [ Time Frame: Baseline to disease progression or discontinuation from study or 28 days after last dose ] [ Designated as safety issue: No ]
    Percentage of participants with OR based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.0. Confirmed response are those that persist on repeat imaging study at least 4 weeks after initial documentation of response. CR are defined as disappearance of all lesions (target and/or non target). PR are those with at least 30% decrease in sum of the longest dimensions of target lesions taking as a reference the baseline sum longest dimensions, with non target lesions not increased or absent.
  • Duration of Response (DR) [ Time Frame: Baseline to disease progression or death or discontinuation from study or 28 days after last dose ] [ Designated as safety issue: No ]
    Time in weeks from the first documentation of objective tumor response to objective tumor progression or death due to any cause. Duration of tumor response was calculated as (the date of the first documentation of objective tumor progression or death due to cancer minus the date of the first CR or PR that was subsequently confirmed plus 1) divided by 7.
  • One-year Survival Probability [ Time Frame: Baseline until death or until 28 days after last dose for the last participant ] [ Designated as safety issue: No ]
    The 1 year survival probability was defined as the probability of survival at one year after the date of the start of the study treatment based on the Kaplan Meier estimate.
  • EuroQol 5-Dimension Questionnaire (EQ-5D)- Health State Profile Utility Score [ Time Frame: Baseline and End of Treatment (EOT) or Withdrawal ] [ Designated as safety issue: No ]
    EQ-5D: participant rated questionnaire to assess health-related quality of life in terms of a single utility score. Health State Profile component assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression; 1 indicates better health state (no problems); 3 indicates worst health state (eg, "confined to bed"). Scoring formula developed by EuroQol Group assigns a utility value for each domain in the profile. Score is transformed and results in total score range -0.594 to 1.000; higher score indicates better health state.
Progression free survival Overall response rate Duration of tumor control Safety and tolerability Patient reported outcomes
Not Provided
Not Provided
 
A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone
A Multicenter, Randomized, Double-Blind, Controlled Phase 3, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib

This study will test whether treatment with erlotinib plus SU011248 is better than erlotinib alone in patients with advanced/metastatic lung cancer who have received previous treatment with a platinum-based regimen.

Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Carcinoma, Non-Small Cell Lung
  • Drug: erlotinib
    plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
  • Drug: sunitinib
    Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
  • Drug: placebo
    Placebo daily by oral capsules in a continuous regimen
  • Experimental: 1
    Interventions:
    • Drug: erlotinib
    • Drug: sunitinib
  • Active Comparator: 2
    Interventions:
    • Drug: erlotinib
    • Drug: placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
960
December 2012
July 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients with locally advanced/metastatic non-small cell lung cancer
  • Prior treatment with no more than 2 chemotherapy regimens including a platinum-based regimen

Exclusion Criteria:

  • Prior treatment with any receptor tyrosine kinase inhibitors, VEGF inhibitor (with the exception of bevacizumab) or other angiogenesis inhibitors
  • History of or known brain metastases
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Argentina,   Austria,   Belgium,   Brazil,   Canada,   Chile,   Colombia,   Czech Republic,   Denmark,   Germany,   Greece,   Hong Kong,   Hungary,   Italy,   Korea, Republic of,   Netherlands,   Norway,   Poland,   Russian Federation,   Slovakia,   Spain,   Switzerland,   Taiwan,   Thailand,   United Kingdom
 
NCT00457392
A6181087, SUN1087
Yes
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP